Clinical trial

Super-Selective Intra-Arterial Embolization of Hypervascular Head and Neck Tumors

Name
RG1121599
Description
This phase I trial tests whether embolization done prior to surgery (preoperative) will improve surgical outcomes in head and neck tumors with large amounts of blood vessels (hypervascular). Embolization is a minimally invasive surgical technique performed under angiographic (imaging of blood vessels) guidance. Embolization therapy injects tiny particles into the arteries feeding tumors to cut off their blood supply which may help improve outcomes by preventing blood loss during surgery, reducing surgical times, and shrinking tumors or reducing recurrence.
Trial arms
Trial start
2023-12-21
Estimated PCD
2025-01-31
Trial end
2025-01-31
Status
Withdrawn
Phase
Early phase I
Treatment
Iodixanol
Given via injection
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Other names:
Indixanol, OptiPrep, Visipaque
Angiogram
Undergo diagnostic cerebral angiogram
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Arterial Embolization
Undergo tumor vessel embolization
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Other names:
TAE, Transarterial Embolization
Polyvinyl Alcohol
Given via catheter
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Other names:
9002-89-5, Polydesis, Polyviol, Poval 420, PVA, Vinarol DT
Ethiodized Oil
Given via catheter
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Other names:
8008-53-5, Ethiodol, iodized oil, Lipiodol
Computed Tomography
Undergo head and neck CT scans
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Other names:
CAT Scan, Computed Axial Tomography, CT SCAN
Chart Abstraction
Ancillary studies
Arms:
Treatment (PVA, EOV, tumor vessel embolization)
Primary endpoint
Intraoperative blood loss
Intraoperatively
Eligibility criteria
Inclusion Criteria: * Primary or metastatic extra-axial tumor involving one or more anatomic structures in the head and neck * Vascular supply from one or more branches of the external carotid artery * Planned surgical resection * All stages * Extra-axial head and neck tumor greater than 1 cm in any dimension * Confirmed by contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT) of the head and/or neck * Subjects who have undergone prior therapies are eligible * Adults aged 18-80; no data outside this age range * Minimum of 3-month life expectancy * Estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73 m\^2 * Subjects must be non-pregnant at the time of angiographic intervention * Resectable tumor as determined by the Tumor Board * Medically stable at the time of the planned intervention, despite potential comorbidities * In English or Spanish. All study materials have been professionally translated into Spanish Exclusion Criteria: * Recent hemorrhage or trauma * Pregnancy * Nursing mothers * Contrast medium allergy * Hypersensitivity or known allergy to ethiodized oil, poppy seeds, or poppy seed oil * Uncontrolled or concurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnancy is a contraindication to angiography outside of the emergency setting * Active thyroid disease may be affected by iodinated products * Subject is participating in another clinical trial at the enrollment of the study or duration of the study that can affect the treatment and outcome of the study
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}
Updated at
2023-12-12

1 organization

2 products

2 indications